An HLA-A2 polyepitope vaccine for melanoma immunotherapy

Journal of Immunology

Volumn 163, Issue 7, 1999, Pages 4058-4063

  Mateo, Luis ^c   Gardner, Joy ^c   Chen, Qiyuan ^a   Schmidt, Christopher ^c   Down, Michelle ^c   Elliott, Suzanne L ^c   Pye, Stephanie J ^c   Firat, Hüseyin ^b   Lemonnier, Francois A ^b   Cebon, Jonathon ^a   Suhrbier, Andreas ^c  

^a AUSTIN HEALTH   (Australia)

^b INSTITUT PASTEUR   (France)

^c NONE

Author keywords

[No Author keywords available]

Indexed keywords

CD8 ANTIGEN; EPITOPE; HLA A2 ANTIGEN; MELANOMA ANTIGEN; RECOMBINANT VACCINE;

ARTICLE; CANCER IMMUNOTHERAPY; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; DOWN REGULATION; HUMAN; HUMAN CELL; MELANOMA; PRIORITY JOURNAL; TARGET CELL; TRANSGENIC MOUSE; TUMOR ESCAPE;

AMINO ACID SEQUENCE; ANIMALS; ANTIGENS, NEOPLASM; BASE SEQUENCE; CANCER VACCINES; CYTOTOXICITY TESTS, IMMUNOLOGIC; EPITOPES, T-LYMPHOCYTE; HLA-A2 ANTIGEN; HUMANS; LYMPHOCYTE ACTIVATION; MELANOMA; MICE; MICE, TRANSGENIC; MOLECULAR SEQUENCE DATA; NEOPLASM PROTEINS; T-LYMPHOCYTES, CYTOTOXIC; TUMOR CELLS, CULTURED; VACCINATION; VACCINIA VIRUS;

EID: 0033213988     PISSN: 00221767     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (53)

1. Nestle, F. O., S. Alijagic, M. Gilliet, Y. Sun, S. Grabbe, R. Dummer, G. Burg, and D. Schadendorf. 1998. Vaccination of melanoma patients with peptide- or tumor lysate-pulsed dendritic cells. Nat. Med. 4:328.
2. Rosenberg, S. A., J. C. Yang, D. J. Schwartzentruber, P. Hwu, F. M. Marincola, S. L. Topalian, N. P. Restifo, M. E. Dudley, S. L. Schwarz, P. J. Spiess, J. R. Wunderlich, M. R. Parkhurst, Y. Kawakami, C. A. Seipp, J. H. Einhorn, and D. E. White. 1998. Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma. Nat. Med. 4:321.
3. Pardoll, D. M. 1998. Cancer vaccines. Nat. Med. 4:525.
4. Kim, C. J., D. R. Parkinson, and F. Marincola, 1998. Immunodominance across HLA polymorphism: implications for cancer immunotherapy. J. Immunother. 21:1.
5. Disis, M. L., J. R. Gralow, H. Bernhard, S. L. Hand, W. D. Rubin, and M. A. Cheever. 1996. Peptide-based, but not whole protein, vaccines elicit immunity to HER-2/neu, oncogenic self-protein. J. Immunol. 156:3151.
6. Moss, D. J., C. Schmidt, S. L. Elliott, A. Suhrbier, S. Burrows, and R. Khanna. 1996. Strategies involved in developing an effective vaccine to EBV-associated diseases. Adv. Cancer Res. 69:213.
7. Yoon, J. W., H. S. Jun, and P. Santamaria. 1998. Cellular and molecular mechanisms for the initiation and progression of beta cell destruction resulting from the collaboration between macrophages and T cells. Autoimmunity 27:109.
8. Kobayashi, M., H. Kobayashi, R. B. Pollard, and F. Suzuki. 1998. A pathogenic role of Th2 cells and their cytokine products on the pulmonary metastasis of murine B16 melanoma. J. Immunol. 160:5869.
9. Fernando, G. J., T. J. Stewart, R. W. Tindle, and I. H. Frazer. 1998. Vaccine-induced Th1-type responses are dominant over Th2-type responses in the short term whereas pre-existing Th2 responses are dominant in the longer term. Scand. J. Immunol. 47:459.
10. Qin, Z., G. Richter, T. Schuler, S. Ibe, X. Cao, and T. Blankenstein. 1998. B cells inhibit induction of T cell-dependent tumor immunity. Nat. Med. 4:627.
11. Apostolopoulos, V., C. Osinski, and I. F. McKenzie. 1998. MUC1 cross-reactive Gal α(1, 3)Gal antibodies in humans switch immune responses from cellular to humoral. Nat. Med 4:315.
12. Lehmann, F., M. Marchand, P. Hainaut, P. Pouillart, X. Sastre, H. Ikeda, T. Boon, and P. G. Coulie. 1995. Differences in the antigens recognized by cytolytic T cells on two successive metastases of a melanoma patient are consistent with immune selection. Eur. J. Immunol. 25:340.
13. Brasseur, F., D. Rimoldi, D. Lienard, B. Lethe, S. Carrel, F. Arienti, L. Suter, R. Vanwijck, A. Bourlond, Y. Humblet, et al. 1995. Expression of MAGE genes in primary and metastatic cutaneous melanoma. Int. J. Cancer 63:375.
14. Garrido, F., F. Ruiz-Cabello, T. Cabrera, J. J. Perez-Villar, M. Lopez-Botet, M. Duggan-Keen, and P. L. Stern. 1997. Implications for immunosurveillance of altered HLA class I phenotypes in human tumors. Immunol. Today 18:89.
15. Elliott, S. L., S. Pye, T. Le, L. Mateo, J. Cox, L. Macdonald, A. A. Scalzo, C. A. Forbes, and A. Suhrbier. 1998. Peptide based cytotoxic T cell vaccines: delivery of multiple epitopes, help, memory and problems. Vaccine 17:2009.
16. Thomson, S. A., S. L. Elliott, M. A. Sherritt, K. W. Sproat, B. E. Coupar, A. A. Scalzo, C. A. Forbes, A. M. Ladhams, X. Y. Mo, R. A. Tripp, P. C. Doherty, D. J. Moss, and A. Suhrbier. 1996. Recombinant polyepitope vaccines for the delivery of multiple CD8 cytotoxic T cell epitopes. J. Immunol. 157:822.
17. + cytotoxic T cells: implications for vaccine design. Proc. Natl. Acad. Sci. USA 92:5845.
18. Chen, Q., H. Jackson, P. Gibbs, I. D. Davis, J. Trapani, and J. Cebon. 1998. Spontaneous T cell responses to melanoma differentiation antigens from melanoma patients and healthy subjects. Cancer Immunol. Immunother. 47:191.
19. 2m double knockout mice. J. Exp. Med. 185:2043.
20. Vitiello, A., A. Sette, L. Yuan, P. Farness, S. Southwood, J. Sidney, R. W. Chesnut, H. M. Grey, and B. Livingston. 1997. Comparison of cytotoxic T lymphocyte responses induced by peptide or DNA immunization: implications on immunogenicity and immunodominance. Eur. J. Immunol. 27:671.
21. Newberg, M. H., D. H. Smith, S. B. Haertel, D. R. Vining, E. Lacy, and V. H. Engelhard. 1996. Importance of MHC class 1 α2 and α3 domains in the recognition of self and nonself MHC molecules. J. Immunol. 156:2473.
22. Hislop, A. D., M. F. Good, L. Mateo, J. Gardner, M. H. Gatei, R. C. W. Daniel, B. V. Meyers, M. F. Lavin, and A. Suhrbier. 1998. Vaccine induced cytotoxic T lymphocytes protect against retroviral challenge. Nat. Med. 4:1193.
23. Alexander-Miller, M. A., G. R. Leggatt, and J. A. Berzofsky. 1996. Selective expansion of high-or low-avidity cytotoxic T lymphocytes and efficacy for adoptive immunotherapy. Proc. Natl. Acad. Sci. USA 93:4102.
24. Wentworth, P. A., A. Vitiello, J. Sidney, E. Keogh, R. W. Chesnut, H. Grey, and A. Sette. 1996. Differences and similarities in the A2.1-restricted cytotoxic T cell repertoire in humans and human leukocyte antigen-transgenic mice. Eur. J. Immunol. 26:97.
25. Bakker, A. B., S. H. van der Burg, R. J. Huijbens, J. W. Drijfhout, C. J. Melief, G. J. Adema, and C. G. Figdor. 1997. Analogues of CTL epitopes with improved MHC class-I binding capacity elicit anti-melanoma CTL recognizing the wild-type epitope. Int. J. Cancer 170:302.
26. Parkhurst, M. R., M. L. Salgaller, S. Southwood, P. F. Robbins, A. Sette, S. A. Rosenberg, and Y. Kawakami. 1996. Improved induction of melanomareactive CTL with peptides from the melanoma antigen gp100 modified at HLA-A*0201-binding residues. J. Immunol. 157:2539.
27. Momburg, F., J. Roelse, J. C. Howard, G. W. Butcher, G. J. Hammerling, and J. J. Neefjes. 1994. Selectivity of MHC-encoded peptide transporters from human, mouse and rat. Nature 367:648.
28. Peh, C. A., S. R. Burrows, M. Barnden, R. Khanna, P. Cresswell, D. J. Moss, and J. McCluskey. 1998. HLA-B27-restricted antigen presentation in the absence of tapasin reveals polymorphism in mechanisms of HLA class I peptide loading. Immunity 8:531.
29. Braud, V. M., A. J. McMichael, and V. Cerundolo. 1998. Differential processing of influenza nucleoprotein in human and mouse cells. Eur. J. Immunol. 28:625.
30. Fukui, Y., O. Hashimoto, A. Inayoshi, T. Gyotoku, T. Sano, T. Koga, T. Gushima, and T. Sasazuki. Highly restricted T cell repertoire shaped by a single major histocompatibility complex-peptide ligand in the presence of a single rearranged T cell receptor β chain. J. Exp. Med. 188:897.
31. Naftzger, C., Y. Takechi, H. Kohda, I. Hara, S. Vijayasaradhi, A. N. Houghton. 1996. Immune response to a differentiation antigen induced by altered antigen: a study of tumor rejection and autoimmunity. Proc. Natl. Acad. Sci. USA 93:14809.
32. + T lymphocytes. Proc. Natl. Acad. Sci. USA 96:2982.
33. Ossendorp, F., E. Mengede, M. Camps, R. Filius, and C. J. Melief. 1998. Specific T helper cell requirement for optimal induction of cytotoxic T lymphocytes against major histocompatibility complex class II regative tumors. J. Exp. Med. 187:693.
34. Reddish, M., G. D. MacLean, R. R. Koganty, J. Kan-Mitchell, V. Jones, M. S. Mitchell, and B. M. Longenecker. 1998. Anti-MUC1 class I restricted CTLs in metastalic breast cancer patients immunized with a synthetic MUC1 peptide. Int. J. Cancer 76:817.
35. + cytotoxic T-cell responses during chronic viral infection. J. Virol. 68:8056.
36. Lauritzsen, G. F., P. O. Hofgaard, K. Schenck, and B. Bogen. 1998. Clonal deletion of thymocytes as a tumor escape mechanism. Int. J. Cancer 78:216.
37. Staveley-O'Carroll, K., E. Sotomayor, J. Montgomery, I. Borrello, L. Hwang, S. Fein, D. Pardoll, and H. Levitsky. 1998. Induction of antigen-specific T cell anergy: an early event in the course of tumor progression. Proc. Natl. Acad. Sci. USA 95:1178.
38. Albert, M. L., B. Sauter, and N. Bhardwaj. 1998. Dendritic cells acquire antigen from apoptotic cells and induce class I-restricted CTLs. Nature 392:86.
39. Pende, D., L. Accame, L. Pareti, A. Mazzocchi, A. Moretta, G. Parmiani, and L. Moretta. 1998. The susceptibility to natural killer cell-mediated lysis of HLA class I-positive melanomas reflects the expression of insufficient amounts of different HLA class I alleles. Eur. J. Immunol. 28:2384.
40. + T cell induction and complete protective efficacy of malaria DNA vaccination by boosting with modified vaccinia virus Ankara. Nat. Med. 4:397.
41. Toes, R. E., R. C. Hoeben, E. I. van der Voort, M. E. Ressing, A. J. van der Eb, C. J. Melief, and R. Offringa. 1997. Protective anti-tumor immunity induced by vaccination with recombinant adenoviruses encoding multiple tumor-associated cytotoxic T lymphocyte epitopes in a string-of-beads fashion. Proc. Natl. Acad. Sci. USA 94:14660.
42. Thomson, S. A., M. A. Sherritt, J. Medveczky, S. L. Elliott, D. J. Moss, G. J. Fernando, L. E. Brown, and A. Suhrbier. 1998. Delivery of multiple CD8 cytotoxic T cell epitopes by DNA vaccination. J. Immunol. 160:1717.
43. Condon, C., S. C. Watkins, C. M. Celluzzi, K. Thompson, and L. D. Falo, Jr. 1996. DNA-based immunization by in vivo transfection of dendritic cells. Nat. Med. 10:1122.
44. Fallarino, F., C. Uyttenhove, T. Boon, and T. F. Gajewski. 1996. Endogenous IL-12 is necessary for rejection of P815 tumor variants in vivo. J. Immunol. 156:1095.
45. Tuting, T., C. C. Wilson, D M. Martin, Y. L. Kasamon, J. Rowles, D. I. Ma, C. L. Slingluff, Jr., S. N. Wagner, P. van der Bruggen, J. Baar, M. T. Lotze, and W. J. Storkus. 1998. Autologous human monocyte-derived dendritic cells genetically modified to express melanoma antigens elicit primary cytotoxic T cell responses in vitro: enhancement by cotransfection of genes encoding the Th1-biasing cytokines IL-12 and IFN-α. J. Immunol. 160:1139.
46. Kawakami, Y , S. Eliyahu, K. Sakaguchi, P. F. Robbins, L. Rivoltini, J. R. Yannelli, E. Appella, and S. A. Rosenberg. 1994. Identification of the immunodominant peptides of the MART-1 human melanoma antigen recognized by the majority of HLA-A2-restricted tumor infiltrating lymphocytes, J. Exp. Med. 180:347.
47. van der Bruggen, P., J. Bastin, T. Gajewski, P. G. Coulie, P. Boel, C. De Smet, C. Traversari, A. Townsend, and T. Boon. 1994. A peptide encoded by human gene MAGE-3 and presented by HLA-A2 induces cytolytic T lymphocytes that recognize tumor cells expressing MAGE-3. Eur. J. Immunol. 12:3038.
48. Wolfel, T., A. Van Pel, V. Brichard, J. Schneider, B. Seliger, K. H. Meyer zum Buschenfelde, and T. Boon. 1994. Two tyrosinase nonapeptides recognized on HLA-A2 melanomas by autologous cytolytic T lymphocytes. Eur. J. Immunol. 3:759.
49. Kawakami, Y., S. Eliyahu, C. H. Delgado, P. F. Robbins, K. Sakaguchi, E. Appella, J. R. Yannelli, G. J. Adema, T. Miki, and S. A. Rosenberg. 1994. Identification of a human melanoma antigen recognized by tumor-infiltrating lymphocytes associated with in vivo tumor rejection. Proc. Natl. Acad. Sci. USA 91:6458.
50. Salgaller, M. L., A. Afshar, F. M. Marincola, L. Rivoltini, Y. Kawakami, and S. A. Rosenberg. 1995. Recognition of multiple epitopes in the human melanoma antigen gp100 by peripheral blood lymphocytes stimulated in vitro with synthetic peptides. Cancer Res. 55:4972.
51. Coulie, P. G., V. Brichard, A. Van Pel, T. Wolfel, J. Schneider, C. Traversari, S. Mattei, E. De Plaen, C. Lurquin, J. P. Szikora, et al. 1994. A new gene coding for a differentiation antigen recognized by autologous cytolytic T lymphocytes on HLA-A2 melanomas. J. Exp. Med. 180:35.
52. Guilloux, Y., S. Lucas, V. G. Brichard, A. Van Pel, C. Viret, E. De Plaen, F. Brasseur, B. Lethe, F. Jotereau, and T. Boon. 1996. A peptide recognized by human cytolytic T lymphocytes on HLA-A2 melanomas is encoded by an intron sequence of the N-acetylglucosaminyltransferase V gene. J. Exp. Med. 183:1173.
53. Mosse, C. A., L. Meadows, C. J. Luckey, D. J. Kittlesen, E. L. Huczko, C. L. Slingluff, J. Shabanowitz, D. F. Hunt, and V. H. Engelhard. 1998. The class I antigen-processing pathway for the membrane protein tyrosinase involves translation in the endoplasmic reticulum and processing in the cytosol. J. Exp. Med. 187:37.